Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprefact1
2011-004836-76Phase 4Active
- Sponsor
- Urologkliniken Uppsala
- Start
- Oct 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of buserelin in prostate cancer (PCa), sponsored by Urologkliniken Uppsala. Primary endpoint: Testosterone level after 4 months. Started Oct 2011; status: active.
02
Drugs
buserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2011-004836-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004836-76.